search
cross icons

It is important to remain committed to the expansion of Pakistan's healthcare industry. Through innovation, technologically sophisticated procedures, and constant pooling of high-quality resources, we will provide extraordinary healthcare services to the masses, and move Pakistan beyond borders resulting in Martin Dow becoming one of Pakistan's major pharmaceutical groups.

M. JAWED AKHAI

(1962 - 2018)
Founding Chairman
Martin Dow Group

Creating Distinction for Life

That’s what we at Martin Dow have been shaping to lead the future of healthcare.

With an uninterrupted legacy of over half a century, Martin Dow is benchmarked for delivering quality products that continue to contribute to the health of millions of people worldwide. Today, Martin Dow Group remains committed to its Founding Chairman's vision and is better positioned than ever before to deliver quality healthcare to patients worldwide.

Our Journey

  • -
  • 1960
  • 1995

Akhai family enters the Pharmaceutical Industry

  • 1960
  • 1995
  • 2000

Established Martin Dow Pharmaceuticals Ltd.

  • 1995
  • 2000
  • 2010

Commencement of the first manufacturing facility in Lahore, Pakistan

  • 2000
  • 2010
  • 2010

Martin Dow acquired the Roche facility in Pakistan along with the acquisition and brand licensing of the global product lines from Hoffmann-La Roche, Switzerland

  • 2010
  • 2010
  • 2013

Established Seatle (Pvt.) Ltd as a manufacturing facility in Lahore

  • 2010
  • 2013
  • 2016

Recognized as a Global Growth Company at World Economic Forum

  • 2013
  • 2016
  • 2016

Established Martin Dow Healthcare, an international manufacturing facility for nutraceuticals in Gien, France

  • 2016
  • 2016
  • 2017

Acquisition of Merck Germany’s shareholding in Pakistan, along with two manufacturing facilities

  • 2016
  • 2017
  • 2017

Established Martin Dow Marker Ltd. (formerly Merck Pvt. Ltd.)

  • 2017
  • 2017
  • 2021

Inauguration of Martin Dow Pharmaceuticals (former Bristol-Myers Squibb plant) in Meymac, France

  • 2017
  • 2021
  • -

Launch of a new identity for Martin Dow Specialities Ltd.

Mission, Vision & Values

Mission

  • To be one of the most admired companies
  • To be among the fastest growing healthcare companies

Vision

Martin Dow is a Corporate Force that is positioned to create long term value for society and its stakeholders

Values

  • We build products we are proud of
  • We are passionate, agile, and courageous
  • We believe that there’s always room for better
  • We focus on patients’ wellbeing, and everything follows
  • We are here to improve the quality of life for the communities we serve
  • We create opportunities for all our partners to flourish

Chairman's Message

ALI AKHAI

Chairman - Martin Dow Group

WELCOME TO MARTIN DOW

In this increasingly virtual age, the Martin Dow refreshed websites represent the public face of our Group Companies and have been designed as a forum for interaction with our colleagues, our business partners, and our customers. It has taken significant time and effort to think through our Corporate Objectives while developing our new web pages, as we involved everyone in this evolution process to show you the passion, dedication, and commitment of The Martin Dow family.

Our Newly refreshed websites are a true depiction of our Vision, Beliefs, and Values. The Martin Dow story began in 1960 with the establishment of our pharmaceutical distribution business. From 1995 till the present day, we have emerged as the fastest-growing Healthcare Group, with 6 manufacturing facilities in Asia and Europe and representing 13 International Business Partners. In 2013, we were selected “A Global Growth Company ” by the World Economic Forum in Davos, and have never looked back. We continue to earn the trust and respect of our Business Partners and customers for one simple reason—we have great people in our teams. They are experts in their fields, and they bring passion, pride, and experience with a strong service ethos to everything they do.

Martin Dow has one clear Mission: to Create Distinction for Life, which has made us a Customer-Centric Group, ensuring the highest quality of healthcare products are available to our customers. With a proven track record of successful transformations, our new websites are a part of our legacy. In 2021, we set in place our plan to simplify processes and integrate teams with our businesses. From there, we re-imagined the way our business would look and embarked on a new plan to transform, fuelled by digitization, automation, and consolidation, with a smart touch of creativity.

Social Responsibility & Sustainability remain an integral component of our Corporate Strategy as we strive to give back to the communities and markets where we live and operate, through responsible sustainable practices.

While developing our new web pages, you will appreciate the close attention to details of consistency, colour, typography, imagery, simplicity, and functionality, all to enhance the user experience. As you navigate through our websites, you will get to know us better and learn more about the qualities that make Martin Dow an outstanding provider of healthcare products and a wonderful place to build a career.

Thank you for visiting us.

Leadership Team

ALI AKHAI

Chairman - Martin Dow Group

Ali Akhai became the Chairman, Martin Dow Group in October 2018. As an initiative-driven leader, he believes in the significance of diverse business, technological innovation, and talent, ready to lead impact with a desire to enhance the wellbeing of the human race. He is recognized as the face of the Martin Dow Group and has received praise for his in-depth knowledge of numerous facets of the pharmaceutical industry.

After completing his Bachelor of Science business graduate degree (BSc) from Brunel University in the UK, he proceeded to further his education with a double Master's degree. He holds a Master of Science in Global Business from the University of Hertfordshire in the United Kingdom and a Master of Science in International Business Development & Consulting from Novancia Business School in France.

Ali joined the Martin Dow Group of Companies in 2016, and after completing a structured orientation program in Marketing, Finance, Business Development, Human Resources, and Regulatory Affairs, he assumed the role of Business Development Lead, launching eight new items for the Group by mid-2018.

He is playing an essential role in shaping the future of the Martin Dow Group, carrying on his father's vision by guiding the Group's foray into further diversification through successful strategic acquisitions and flexible technologies. As Chairman of the Group, he is leading the 6th Largest Pharmaceutical Group in Pakistan with 2 Healthcare Companies in Europe, into expansion with worldwide partnerships, talent development, and industry influence, to ethically grow through innovation and courage.

He is a visionary and philanthropist, deeply focused on improving the standards of Healthcare, Education and Environment in Pakistan. He represents Pakistan in global events such as World Economic Forum, closely working with global and local key stakeholders to present the Nation’s interest and enhance Pakistan’s international reputation.

JAVED GHULAM MOHAMMAD

Group Managing Director & CEO

Javed is a Group Managing Director and Chief Executive Officer of Martin Dow Group, and under his leadership, the group has experienced unprecedented growth, including the acquisition of the Roche brands and manufacturing facility, leading the Group's growth further through his noteworthy insights.

He is a qualified fellow member of the Institute of Cost & Management Accountants of Pakistan, with over 25 years of experience leading in diversified functions such as Finance, Marketing, International Business, Business Development, Supply Chain, Regulatory Affairs, New Product Development, and Technical Functions.

He has held key positions at a number of leading multinational and national companies, including Abbott Laboratories, Getz Pharma, Briogene, and AJ Research & Pharma (a Saudi Arabian subsidiary of the Al Jomiah Group), the latter two of which he served as the Chief Executive Officer (CEO).

To his credit, he has grown AJ Pharma from a start-up to a global company with a strong presence in both prescription and consumer health markets across seven ASEAN and GCC countries. Under his guidance, the Martin Dow Group continues to grow and set new standards of distinction across the healthcare and pharmaceutical industry in Pakistan and abroad.

DR. ANUM JAWED AKHAI

Group Director Business Growth & Strategy

Dr. Anum entered the Corporate World when she teamed up with Martin Dow Group in 2018, bringing her Dental & Medical experience and knowledge to the pharma table. Dr. Anum did her Bachelor’s in Dental Surgery in 2012. After completing an internship program at University College London, she received a certificate in Orthodontics from the Academy of Straight Wire and Functional Orthodontics (USA). She began her medical career as a private practitioner from 2013 to 2015 and as a lecturer and post-graduate resident from 2015 to 2018.

Post her induction into the pharmaceutical industry, she has been broadening her horizons and scope of business acumen with passion and energy, developing exceptional expertise in the Group’s Business Development and Strategy.

She is an Entrepreneur, Leader, and Philanthropist, leading change in the organization and empowering women. Her formal education and practical exposure in the healthcare sector have exhilarated her to establish and drive the innovative eco-system, helping people and the Organization achieve high levels of growth and value.

ABDUL SAMAD HAROON

Group Chief Financial Officer

Abdul Samad is the Chief Financial Officer and joined the Martin Dow Group in April 2021. At Martin Dow he currently oversees the local and International finance operations along with group’s business strategic projects.

He is a Chartered Accountant and a fellow member of the Institute of Chartered Accountants of Pakistan. Prior to Martin Dow he also worked in GlaxoSmithKline (GSK) and PwC.

Abdul Samad has an extensive career with 20+ years of experience in developing and leading high performance teams in multi culture GSK markets of Pakistan, Saudi Arabia & Morocco. He is commercially savvy with track record of strategy execution, driving organizational growth and delivering transformational commercial and finance projects in complex environments. At GSK he also served as Finance Director on the board for 6 years.

SHAHRUKH MASOOD

Group Director Human Resources & Corporate Communication

Shahrukh joined the Martin Dow Group in 2020 and has since risen to the position of Director Human Resources & Corporate Communication for the group.

He has served as the Director of Human Resources for several organizations and holds over 20 years of experience working in Pakistan, the Middle East, and Africa. His career spans work for a number of prominent national and multinational organizations, including Getz Pharma, Abbott Laboratories Pakistan, Reckitt Benckiser Arabia, and DXB Entertainment

Shahrukh holds a Master's degree in Business Administration with a specialization in Human Resources & Marketing. He is also a certified Leadership Coach from the International Coaching Federation (ICF).

RUSTOM J. BOGA

Group Director Corporate Social Responsibility

Rustom joined the Martin Dow Group in 2017 and is responsible for overseeing the group's Corporate Social Responsibility. He joined the group with over 30 years of extensive knowledge and varied expertise in marketing and communications.

He has worked with a variety of national and multinational corporations, including Unilever, Standard Chartered, Cupola, and Manhattan International. He is a Master of Business Administration (MBA) with majors in Marketing from IBA.

SYED IJLAL HUSSAIN JAFRI

Group Chief Information Officer

Ijlal leads the IT function and is in charge of group IT strategy that includes all entities and sites of the Martin Dow group. In addition to IT, Ijlal also oversees the Creative function, which is also operating at the group level. Prior to joining Martin Dow, he led AJ Pharma Holding in Malaysia as the Chief Information Officer (CIO), where he spearheaded the group’s global IT Strategy, with the presence in major Asian Pacific countries.

Ijlal offers more than 25 years of extensive experience in implementing Enterprise systems, Digital Transformation Strategy, BI initiatives, IT Governance, IT Security, and business continuity planning. Taking reins on digital transformation, the IT organization has been remodeled at group level, emphasizing customer centricity and increasing agile response to shifting business needs.

Graduated from Hamdard University with a Master’s degree in E-Business and MBA in Information Technology. His career started with Servier Pakistan, and he has since worked his way up to various key positions.

USMAN JAVED ALTAF

Director Legal & Intellectual Property

Usman is looking after the legal & IP matters of all companies falling under the Martin Dow banner. He has diversified work experience having worked with Telecom, IT, Tobacco, Energy, Pharmaceuticals, Construction, and the Automobile industries.

With a focus on M&As, IP, Dispute Management & Corporate Structuring, he has been engaged in setting up and managing various national and international projects. Prior to joining Martin Dow, he was heading the legal function at the Lucky Group and was involved in establishing KIA & an LNG Terminal in Pakistan and manufacturing facilities in the EMEA region.

Usman is a qualified Barrister, member of the Honourable Society of Lincolns Inn and read for is LLB (Hons.) at University of Kent, Canterbury with a distinction in IP and holds an LLM degree from City University London, England.

ATIF KHAN

Group Head Internal Audit & Risk Management

Atif joined the Martin Dow Group in 2018 and is currently leading the Internal Audit & Risk Management department.

His primary role is to create and implement an independent audit function to bring value to the Group's operations while also giving reasonable assurance on the Group's risk management.

He has substantial GRC experience gained across Pakistan and the Gulf region he has formerly worked with notable companies including Sanofi Aventis, Oman Air, and National Investment Trust Limited.

He is a Fellow Cost and Management Accountant (FCMA), a Certified Internal Auditor (CIA), and a Certified Information System Auditor (CISA).

Achievements

6th Largest Pharmaceutical Group in Pakistan

Recognition in the World Economic Forum 2013. Martin Dow is the first Pakistani pharmaceutical company recognized as a Global Growth Company (GGC) of the World Economic Forum in 2013, joining over 370 companies globally in this community.

Blog Image

Martin Dow Marker Ltd. Receives Halal Certification by SANHA Pakistan

Martin Dow Marker Ltd. is pleased to announce that all its Soft Gelatin Capsule brands are now Halal Certified by SANHA Pakistan, one of the most reputed bodies for Halal certification.

Blog Image

Presence in World Economic Forum

Co-host to the Pakistan Breakfast at the World Economic Forum with the Pathfinder group from the year 2016 till the year 2020.

Blog Image

Recipients of Various CSR & Exports Awards

Martin Dow won CSR and Exporter awards for 5 consecutive years.

Blog Image

Recognition in the World Economic Forum 2013

Martin Dow is the first Pakistani pharmaceutical company recognized as a Global Growth Company (GGC) at the World Economic Forum in 2013, joining over 370 companies globally in this community.

Blog Image

Martin Dow Launches Day Care Facility

Launch of Day Care Facility at Corporate Office

Blog Image

Martin Dow Specialities Signs Distribution Agreement

Martin Dow Specialties signed distribution agreement with key principals including Eli Tech, Boule, Diamond Diagnostics and others

Blog Image

Established 2 Bone Marrow Transplant Rooms at Shaukat Khanum Cancer Hospital & Research Centre

Donated Shaukat Khanum Memorial Cancer Hospital & Research Center in Karachi to establish 2 Bone Marrow Transplant rooms

Blog Image

ANSM Inspection Sub: Renewal for Martin Dow Pharmaceuticals GMP Certification

ANSM (logo) inspection – renewal for Martin Dow Pharmaceuticals GMP certification

Blog Image

Martin Dow Group Launches New Function of Trade Marketing

New function of trade marketing has been launched to further drive value and growth for Martin Dow brands.

Blog Image

Martin Dow Marker Ltd Receives A+ and A1 Rating by PACRA

PACRA has assigned Martin Dow Market Ltd. A+ long-term rating and short-term A1 rating with a stable outlook

Blog Image

Recipients of France Trade Performance Awards

Recipient of an exclusive award for our ever-growing quality manufacturing facility in France in 2019 at the 3rd Pakistan – France Trade Performance Awards.

Blog Image

Martin Dow Group Become Global

Martin Dow Group enters the regions of Central Asia and Africa

Blog Image

Martin Dow Healthcare Celebrates Launch of SAP S/4HANA

Martin Dow Healthcare celebrates launch of SAP S/4HANA at their Gien site in France. This new transformation will allow our cross-border team to simplify their processes, drive data for smooth decision making in real-time and adapt instantly to growing challenges in new normal.

Blog Image

37 Products are in #1 Category

37 Products of Martin Dow Group are #1 in their respective molecules

Blog Image

Consistent Award Winner

Martin Dow received the ‘Winner of Best Export Performance Award’ in the pharmaceutical category for the 5th consecutive time, awarded by the Government of Pakistan.

Blog Image

Prestigious PFBA Awards

Martin Dow has received 1st Prize in Pharmaceutical category by the Pakistan France Business Alliance for two consecutive years; 2014-2015 and 2015-2016.

Acquisition

Martin Dow Promotes Better Living

Our acquisitions have resulted in the exchange of strategic ideas, operational infrastructure, and a powerhouse of talent that is synonymous with quality healthcare.

Acquisitions Pakistan

Our belief in improving the quality of life is by facilitating people's access to quality medicines, which has led us to make sizable strategic acquisitions of healthcare giants like Roche and Merck in Pakistan.

Cross Border Acquisitions

We build products we are proud of by enhancing the standard of our services and exceeding customer expectations. We have also crossed borders to establish two manufacturing plants; Martin Dow pharmaceuticals in Meymac, France, and Martin Dow Healthcare in Gien, France.

have queries?

Connect With Us

For information and queries:

+92 21 111 111 634

For information and queries:

+92 21 350 605 41